It seems like there will never be enough “thank you’s” for the incredible doctors, nurses technicians and support staff members who are working around the clock to help patients with this dangerous disease. It is their dedication, determination and spirit that allow Johns Hopkins to deliver the promise of medicine.
Six Key Takeaways for Entrepreneurs and Startups on Fundraising and How Investors View the Post-Coronavirus Landscape Over 200 entrepreneurs, startup company executives and those with aspirations of starting a BioHealth company turned in for a live, virtual panel discussion to learn about how COVID-19 is impacting access to the capital every company needs to succeed.
Panelists included notable investors such as Andrea Alms, Co-Fund Manager at BioHealth Capital; Adam Dakin, Managing Director at DreamIT HealthTech; Matthew Miessau, Associate at Epidarex Capital; and Adair Newhall, Principal at Greenspring Associates.
Biological innovations could help us meet some of the great global challenges of our time. This new infographic from McKinsey Global Institute shows the potential impact of the #BioRevolution.
The Children’s National Research Institute recently released its 2019-2020 academic annual report, titled 150 Years Stronger Through Discovery and Care to mark the hospital’s 150th birthday. Not only does the annual report give an overview of the institute’s research and education efforts, but it also gives a peek in to how the institute has mobilized to address the coronavirus pandemic.
“Our inaugural research program in 1947 began with a budget of less than $10,000 for the study of polio — a pressing health problem for Washington’s children at the time and a pandemic that many of us remember from our own childhoods,” says Vittorio Gallo, Ph.D., chief research officer at Children’s National Hospital and scientific director at Children’s National Research Institute. “Today, our research portfolio has grown to more than $75 million, and our 314 research faculty and their staff are dedicated to finding answers to many of the health challenges in childhood.”
Image: Children’s National Research Institute directors Vittorio Gallo, Ph.D., and Mark Batshaw, M.D.
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® REIT, is the first and longest-tenured owner, operator, and developer uniquely focused on collaborative life science, technology , and agtech campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in life science, technology, and agtech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success.
Students across the University System of Maryland are graduating. But there are no auditoriums and arenas packed with people, cheering and taking photos as their children, grandchildren, spouses, parents and friends cross the stage. There is no stage. But there are virtual ceremonies online, produced with as much fanfare as our universities can create.
This isn’t the way graduates wanted to celebrate their enormous accomplishment. It isn’t how our universities wanted to celebrate their graduates. But COVID-19 has subordinated what we want to do in service of what we need to do — for the safety of our students, faculty, staff and neighbors.
Remote medicine. Telehealth. Digital medicine. Virtual visits.
Whatever it might be called, Children’s National Hospital (Children’s National) has been developing and deploying innovative telemedicine protocols, technologies and approaches for nearly two decades.
So when the pandemic hit the region full force in mid-March 2020, Children’s National was ready.
As COVID-19 took hold, the way patients engaged with medical professionals shifted nearly overnight. What was once seen as the future of medical treatment had suddenly, and perhaps irrevocably, been transformed into the standard of care for children and adults unable or unwilling to physically visit their healthcare provider because of the pandemic.
The National Science Foundation’s Innovation Corps (I-Corps™) program uses experiential education to help researchers gain valuable insight into entrepreneurship, starting a business or industry requirements and challenges.
I-Corps enables the transformation of invention to impact. The curriculum integrates scientific inquiry and industrial discovery in an inclusive, data-driven culture driven by rigor, relevance, and evidence. Through I-Corps training, researchers can reduce the time to translate a promising idea from the laboratory to the marketplace.
Image: https://www.nsf.gov
“5 Questions With……” is a new BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. We’re happy to have NeoImmuneTech’s Byung Ha Lee as our 2nd guest.
Byung Ha Lee is the Director, R&D at NeoImmuneTech, Inc. With degrees from Korea University, and his Ph.D. in Medical Sciences-immunology and microbiology from the University of Florida College of Medicine. He has extensive industry experience over 15 years in translational research, business development, field KOL interaction, leading strategic and research planning of drug development. Byung Ha finished his postdoctoral training at the NIAID at NIH.
BARDA is dispatching another billion dollars-plus for the war on Covid-19, lining up 300 million doses for the US that could start arriving as soon as October.
Allied with researchers at Oxford University on one of the leading vaccines now in development for Covid-19, AstraZeneca reported that it has secured more than $1 billion from BARDA for the development, production and delivery of the vaccine, starting in the fall. The injection dwarfs the additional £84 million ($102 million) in funding for 30 million doses (up to 100 million doses) from the United Kingdom, which envisions inoculating at least half its population by September.
